Literature DB >> 26425874

Ventilatory Management During Normothermic Ex Vivo Lung Perfusion: Effects on Clinical Outcomes.

Pier Paolo Terragni1, Vito Fanelli, Massimo Boffini, Claudia Filippini, Paola Cappello, Davide Ricci, Lorenzo Del Sorbo, Chiara Faggiano, Luca Brazzi, Giacomo Frati, Federico Venuta, Luciana Mascia, Mauro Rinaldi, V Marco Ranieri.   

Abstract

BACKGROUND: During ex vivo lung perfusion (EVLP), fixed ventilator settings and monitoring of compliance are used to prevent ventilator-induced lung injury (VILI). Analysis of the airway pressure-time curve (stress index) has been proposed to assess the presence of VILI. We tested whether currently proposed ventilator settings expose lungs to VILI during EVLP and whether the stress index could identify VILI better than compliance.
METHODS: Flow, volume, and airway opening pressure were collected continuously during EVLP. Durations of mechanical ventilation, intensive care unit (ICU) and hospital lengths of stay were recorded in lung recipients.
RESULTS: Fourteen lungs underwent EVLP and were transplanted. In 5 lungs, 95 ± 2% of the stress index values were within the 0.95 to 1.05 range (protected); in the remaining nine lungs, 69 ± 1% of the values were greater than 1.05 and 15 ± 3% were less than 0.95 (nonprotected). There was a significant (P < 0.05) increase in cytokine concentrations after 4 hours of EVLP in the nonprotected lungs. Durations of mechanical ventilation, ICU, and hospital lengths of stay were shorter in recipients of protected than that of nonprotected lungs (P < 0.05). There was no correlation between compliance during EVLP and duration of mechanical ventilation or ICU and hospital lengths of stay in recipients, but the stress index during EVLP was significantly correlated with the duration of mechanical ventilation and with ICU and hospital lengths of stay (P < 0.05).
CONCLUSIONS: This small, preliminary study shows that ventilator settings currently proposed for EVLP may expose lungs to VILI. Use of the stress index to personalize ventilator settings needs to be tested in further clinical studies.

Entities:  

Mesh:

Year:  2016        PMID: 26425874     DOI: 10.1097/TP.0000000000000929

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  5 in total

1.  Airway pressure release ventilation during ex vivo lung perfusion attenuates injury.

Authors:  J Hunter Mehaffey; Eric J Charles; Ashish K Sharma; Dustin T Money; Yunge Zhao; Mark H Stoler; Christine L Lau; Curtis G Tribble; Victor E Laubach; Mark E Roeser; Irving L Kron
Journal:  J Thorac Cardiovasc Surg       Date:  2016-09-22       Impact factor: 5.209

2.  Porcine slaughterhouse lungs for ex vivo lung perfusion - a pilot project.

Authors:  Katharina Kalka; Zoe Keldenich; Henning Carstens; Gero Hilken; Carolin Olbertz; Nikolaus Pizanis; Markus Kamler; Gerald Reiner; Achim Koch
Journal:  Am J Transl Res       Date:  2020-10-15       Impact factor: 4.060

3.  Extracorporeal membrane oxygenation after lung transplantation: risk factors and outcomes analysis.

Authors:  Massimo Boffini; Erika Simonato; Davide Ricci; Fabrizio Scalini; Matteo Marro; Stefano Pidello; Matteo Attisani; Paolo Solidoro; Paolo Olivo Lausi; Vito Fanelli; Cristina Barbero; Luca Brazzi; Mauro Rinaldi
Journal:  Ann Cardiothorac Surg       Date:  2019-01

4.  A Novel Negative Pressure-Flow Waveform to Ventilate Lungs for Normothermic Ex Vivo Lung Perfusion.

Authors:  Christopher M Bobba; Kevin Nelson; Curtis Dumond; Emre Eren; Sylvester M Black; Joshua A Englert; Samir N Ghadiali; Bryan A Whitson
Journal:  ASAIO J       Date:  2021-01-01       Impact factor: 3.826

5.  Custodiol-MP for ex vivo lung perfusion - A comparison in a porcine model of donation after circulatory determination of death.

Authors:  Katharina Kalka; Zoe Keldenich; Henning Carstens; Björn Walter; Ursula Rauen; Arjang Ruhparwar; Alexander Weymann; Markus Kamler; Gerald Reiner; Achim Koch
Journal:  Int J Artif Organs       Date:  2021-02-02       Impact factor: 1.595

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.